| Inlyta (axitinib) / Pfizer |
ChiCTR2000037024: Neoadjuvant therapy of Toripalimab plus Axitinib for Von Hipple-Lindau disease associated clear cell renal cell carcinoma: a single-arm, single-center, prospective study |
|
|
| Recruiting | 4 | 20 | China | Neoadjuvant therapy of Toripalimab plus Axitinib follow by nephrone-sparing surgery | Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine ; Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Self-financing | Von Hippel–Lindau disease | | | | |
KEYNOTE 426, NCT02853331 / 2016-000588-17: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) |
|
|
| Active, not recruiting | 3 | 861 | NA | Pembrolizumab, MK-3475, KEYTRUDA®, Axitinib, INLYTA®, Sunitinib, SUTENT® | Merck Sharp & Dohme LLC | Renal Cell Carcinoma | 10/18 | 12/25 | | |
|
|
|
|
AxiPRO, NCT04764487: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line |
|
|
| Recruiting | 3 | 178 | Europe | KidneyPRO, web-application, standard follow-up | Weprom, Pfizer, FLGXPL | Renal Cell Carcinoma Metastatic | 06/23 | 06/25 | | |
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer |
|
|
| Active, not recruiting | 3 | 421 | RoW | Biological : Toripalimab Drug: Axitinib, sunitinib | Shanghai Junshi Bioscience Co., Ltd. | Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | 06/23 | 06/23 | | |
| Completed | 3 | 886 | Europe, Canada, Japan, US, RoW | Avelumab (MSB0010718C), Axitinib (AG-013736), Inlyta, Sunitinib, Sutent | Pfizer | Renal Cell Cancer | 08/23 | 06/24 | | |
|
|
|
|
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy |
|
|
| Recruiting | 3 | 430 | Europe | Concomitant coaching | AIO-Studien-gGmbH, Pfizer, Crolll Gmbh | Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | 01/24 | 07/24 | | |
| Recruiting | 3 | 1250 | Europe | Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA | Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London | Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | 05/32 | 05/32 | | |
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing |
|
|
| Active, not recruiting | 3 | 62 | Europe, Canada, Japan, US, RoW | Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600 | Pfizer | Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors | 09/26 | 09/26 | | |
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas |
|
|
| Active, not recruiting | 2/3 | 255 | Europe | Axitinib, Sandostatin LAR, Placebo | Grupo Espanol de Tumores Neuroendocrinos, Pfizer | Neuroendocrine Tumors, Advanced Cancer | 08/21 | 10/21 | | |
FRUSICA-2, NCT05522231: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma |
|
|
| Recruiting | 2/3 | 264 | RoW | fruquintinib+sintilimab, HMPL-013 + IBI308, axitinib / everolimus, fruquintinib, HMPL-013 | Hutchison Medipharma Limited | Advanced Renal Cell Carcinoma | 11/24 | 03/25 | | |
NCT06020352: The Efficacy and Safety of KN046 Combined With Axitinib |
|
|
| Recruiting | 2/3 | 20 | RoW | KN046 plus Axitinib, surgical resection and selective adjuvant therapy with KN046 | Shanghai Pulmonary Hospital, Shanghai, China | NSCLC | 07/25 | 07/25 | | |
2011-002029-24: EVALUATION OF THE EFFECTIVENESS OF AXITINIB IN PATIENT WITH HEPATOCELLULAR CARCINOMA PROGRESSED WITH SORAFENIB VALUTAZIONE DELL'EFFICACIA DI AXITINIB IN PAZIENTI CON CARCINOMA EPATOCELLULARE GIA' TRATTATI CON SORAFENIB |
|
|
| Ongoing | 2 | 46 | Europe | AXITINIB, NA, Tablet | UNIVERSITA' CAMPUS BIOMEDICO, PFIZER ITALIA S.R.L. | Hepatocellular carcinoma (HCC) carcinoma epatocellulare (HCC), Hepatocellular carcinoma (HCC) Carcinoma epatocellulare, Diseases [C] - Cancer [C04] | | | | |
2014-003227-21: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract Studio di fase 2 con Inlyta® (Axitinib) nel tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico |
|
|
| Ongoing | 2 | 26 | Europe | Axitinib, AG-013736, Coated tablet, Inlyta | Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Pfizer Italy | recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, Diseases [C] - Cancer [C04] | | | | |
NCT02402777: A Study Of Effectiveness Of Axitinib (CT), In Comparison With Axitinib - Pfizer (INLYTA) Confirmed Objective Response (ORR) In Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 280 | Europe, RoW | Axitinib (CT), AG-013736, Axitinib (Pfizer), INLYTA | Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research | Solid Tumors | 02/15 | 10/17 | | |
2011-000900-16: A randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma |
|
|
| Ongoing | 2 | 52 | Europe | Axitinib, Lomustine, AG-013736, Cecenu (Lomustine), Cecenu (Lomustine) | UZ BRUSSEL, UZ Brussel | • Patients with recurrent central nervous system glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation therapy and alkylating chemotherapy. • No concomitant treatment with enzyme inducing anti-epileptic drugs (EIAED) | | | | |
2011-001793-26: A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma (MAXIM) |
|
|
| Ongoing | 2 | 48 | Europe | Axitinib, Metformin, (AG-013736), Metformin, Metformin | Royal Marsden Hospital, Pfizer | Advanced BRAF mutant melanoma | | | | |
2014-003811-13: Improving treatment selection in patients with cancer using a personalized screening test Het beter selecteren van een behandeling voor patiënten met kanker met behulp van een gepersonaliseerde screening test. |
|
|
| Ongoing | 2 | 70 | Europe | Palbociclib, Axitinib, Selumetinib, Gefitinib, PD-0332991, PF-04449913, PF-05212384, AG-013736, AZD6244, AZD2014, AZD5363, ZD1839, Capsule, hard, Tablet, Lyophilisate for solution for infusion, Capsule, Inlyta, Iressa | Antoni van Leeuwenhoek - Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital - Netherlands Cancer Institute, Pfizer Inc., AstraZeneca | Colorectal cancer and non-small cell lung cancer colorectaal carcinoom en niet-kleincellig longkanker, colorectal cancer and lung cancer Dikkedarmkanker en longkanker, Diseases [C] - Cancer [C04] | | | | |
2017-000619-17: A study to see how effective the drug (Axitinib) is at preventing cancer cells from growing and to see if this means that patients with kidney cancer require less extensive surgery. |
|
|
| Not yet recruiting | 2 | 20 | Europe | Inlyta, Film-coated tablet, Inlyta | Common Services Agency (CSA), Pfizer | Venous tumour thrombus in clear cell renal cell cancer with venous invasion, kidney cancer, Diseases [C] - Cancer [C04] | | | | |
NCT02636725: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas |
|
|
| Completed | 2 | 33 | US | Axitinib, Inlyta, Pembrolizumab, MK-3475, Keytruda | Jonathan Trent, MD, PhD, Merck Sharp & Dohme LLC, Pfizer | Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas | 05/18 | 03/23 | | |
2017-004048-38: Avelumab in combination with Axitinib in patients with advanced Thymic tumours Avelumab in combinazione con Axitinib in pazienti con carcinomi timici in stadio avanzato |
|
|
| Ongoing | 2 | 33 | Europe | Avelumab, INLYTA, [MSB0010718C], [AG-013736], Solution for infusion, Coated tablet, INLYTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE | ISTITUTO EUROPEO DI ONCOLOGIA, PFIZER S.r.l | Histologically confirmed advanced Thymoma B3 or Thymic carcinoma inoperable (Masaoka Stage IIIb or IV). Pazienti affetti da timoma avanzato B3 o carcinoma timico inoperabile (stadio IIIb o IV), advanced thymic carcinoma carcinoma timico avanzato, Diseases [C] - Cancer [C04] | | | | |
2018-003998-96: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST |
|
|
| Not yet recruiting | 2 | 58 | Europe | Axitinib, AVELUMAB, [63539-026], [EU/1/17/1214/001], Coated tablet, Concentrate for solution for infusion, Inlyta, Bavencio | Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Centrum Onkologii – Instytut im. Marii Skłodowskiej – Curie, Pfizer Polska, Maria Sklodowska-Curie National Research Istitute of Oncology, Pfizer Ltd | GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy, Gastrointestinal Stromal Tumor (GIST), Diseases [C] - Cancer [C04] | | | | |
NCT02579811: Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer |
|
|
| Completed | 2 | 40 | US | Axitinib | Case Comprehensive Cancer Center | Metastatic Renal Cell Cancer | 08/19 | 06/23 | | |
SuAx, NCT03592199: Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib |
|
|
| Active, not recruiting | 2 | 7 | RoW | Sunitinib, Axitinib | Instituto do Cancer do Estado de São Paulo, Pfizer | Clear Cell Renal Cell Carcinoma | 12/19 | 12/22 | | |
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling |
|
|
| Not yet recruiting | 2 | 300 | Europe | Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo | Rigshospitalet, Roche, Pfizer | Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04] | | | | |
2019-004098-23: Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study). Studio di fase II sull’uso in prima linea di avelumab in combinazione con axitinib intermittente in pazienti con carcinoma renale metastatico (studio Tide-A) |
|
|
| Ongoing | 2 | 75 | Europe | Inlyta, Avelumab, [Axitinib], [axitinib], [Avelumab], Film-coated tablet, Solution for infusion, INLYTA - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE, INLYTA - 3 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALLUMINIO/ALLUMINIO) 56 COMPRESSE, INLYTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE | CONSORZIO ONCOTECH, Pfizer | metastatic renal cell carcinoma Carcinoma renale metastatico, metastatic renal cell carcinoma Carcinoma renale metastatico, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 20 | | axitinib | Peking University First Hospital; Peking University First Hospital, the National Natural Science Foundation of China (grant 81572506; 81872081)；Peking University Health Science Center 985 Action Plan (grant BMU2018WRLJ001) | Von Hippel-Lindau (VHL) Disease | | | | |
NCT01263769: Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) |
|
|
| Completed | 2 | 39 | US | Axitinib, AG-013736 | M.D. Anderson Cancer Center, Pfizer | Kidney Cancer | 02/21 | 06/23 | | |
|
|
AXAGIST, NCT04258956: A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy |
|
|
| Recruiting | 2 | 58 | Europe | Axitinib, Avelumab | Maria Sklodowska-Curie Institute - Oncology Center | Gastrointestinal Stromal Tumors | 04/21 | 04/23 | | |
NCT02638428: Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy |
|
|
| Recruiting | 2 | 90 | RoW | CancerSCAN™, Ifosfamide, Carboplatin, Etoposide, Fludarabine, Cytarabine, Pazopanib, Sorafenib, Axitinib, Crizotinib, Dasatinib, Erlotinib, Everolimus, Imatinib, Ruxolitinib, Vandetanib, Vemurafenib, Trastuzumab | Samsung Medical Center, Ministry of Health, Republic of Korea | Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML | 12/21 | 12/23 | | |
ChiCTR2000039666: Efficacy and safety of axitinib combined with PD1 inhibitor neoadjuvant treatment of locally advanced renal cell carcinoma: a single center single arm phase II clinical study |
|
|
| Recruiting | 2 | 11 | | sintilimab | Cancer Center of Sun Yat-Sen University; Cancer Center of Sun Yat-Sen University, Innovent Biologics (Suzhou) Co. Ltd. | renal cell carcinoma | | | | |
NCT03941795: Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma |
|
|
| Recruiting | 2 | 99 | RoW | JS001(Toripalimab Injection), Axitinib 1 MG [Inlyta], JS001 and Axitinib | Peking University Cancer Hospital & Institute | Advanced Mucosal Melanoma | 06/22 | 12/22 | | |
| Recruiting | 2 | 30 | RoW | TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®) | Peking University Cancer Hospital & Institute | Mucosal Melanoma | 07/22 | 12/22 | | |
SAARCC, NCT04958473: A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | Sintilimab, Tyvyt, IBI 308, Axitinib, Inlyta | Tianjin Medical University Second Hospital | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | 08/22 | 08/25 | | |
PANDORA, NCT04995016: Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 18 | RoW | Pembrolizumab, Keytruda, Axitinib, Inlyta | Tianjin Medical University Second Hospital | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | 08/22 | 08/23 | | |
2022-001150-35: Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study). Studio di fase II sull’intensificazione di axitinib più nivolumab rispetto a nivolumab da solo dopo l’induzione con nivolumab più ipilimumab in pazienti con mRCC senza una precedente risposta completa (studio AxIn). |
|
|
| Not yet recruiting | 2 | 118 | Europe | Inlyta, [Axitinib], Film-coated tablet, Inlyta 3 mg, Inlyta 5MG, inlyta 1 mg | CONSORZIO ONCOTECH, Pfizer S.r.L | Metastatic renal cell carcinoma Carcinoma a cellule renali metastatico, Metastatic renal cell carcinoma Carcinoma a cellule renali metastatico, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 40 | Europe | Axitinib, Avelumab | The Netherlands Cancer Institute, Pfizer | Renal Cell Carcinoma | 01/23 | 01/25 | | |
|
| Terminated | 2 | 61 | Europe, US, RoW | Avelumab (MSB0010718C), Bavencio, Axitinib (AG-013736), Inlyta | Pfizer | Non-Small Cell Lung Cancer, Urothelial Cancer | 02/23 | 02/23 | | |
NCT04118855: Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma |
|
|
| Completed | 2 | 20 | RoW | Toripalimab, anti-PD-1 monoclonal antibody, Axitinib | RenJi Hospital | Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma | 02/23 | 03/23 | | |
2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Un estudio de combinaciones inhibidoras de puntos de control inmunitario con Axitinib en pacientes con carcinoma de células renales no tratado previamente localmente avanzado no resectable o metastásico |
|
|
| Not yet recruiting | 2 | 210 | Europe | tiragolumab, PD1-LAG3, Pembrolizumab, RO7092284/F03-01, RO7247669/F01-01, RO7223188, Concentrate for solution for infusion, Solution for infusion, Film-coated tablet, INLYTA®, KEYTRUDA® | Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd | Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Carcinoma de células renales localmente avanzado no resectable o carcinoma de células renales metastásico, Clear Cell Renal cell carcinoma (RCC), is the most common type of kidney cancer El carcinoma de células renales (CCR) de células claras es el tipo de cáncer de riñón más común, Diseases [C] - Cancer [C04] | | | | |
NCT03990571: Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma |
|
|
| Completed | 2 | 36 | US | Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Axitinib, AG-013736, AG013736, Inlyta | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma | 03/23 | 03/23 | | |
NCT05420220: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 75 | Europe | Axitinib Oral Tablet, Avelumab | Consorzio Oncotech, Clinical Research Technology S.r.l. | Renal Carcinoma Metastatic | 09/23 | 10/24 | | |
| Active, not recruiting | 2 | 31 | US | Nivolumab, Opdivo, AG013736, Axitinib, INLYTA | Yana Najjar, Pfizer, Bristol-Myers Squibb | Advanced Melanoma, Unresectable Melanoma | 04/24 | 02/29 | | |
NCT03595124: A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) |
|
|
| Active, not recruiting | 2 | 40 | US | Axitinib, AG 013736, AG-013736, AG013736, Inlyta, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo | National Cancer Institute (NCI) | Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma | 09/27 | 09/27 | | |
NCT04459663: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. |
|
|
| Not yet recruiting | 2 | 50 | RoW | Toripalimab injection combine with Axitinib | Li Zhang, MD | Non-small Cell Lung Cancer | 09/23 | 12/23 | | |
NCT05172440: A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC |
|
|
| Active, not recruiting | 2 | 20 | RoW | tislelizumab combined with axitinib | Hongqian Guo | Neoadjuvant Therapy | 11/23 | 10/24 | | |
NCT03839498: Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma |
|
|
| Recruiting | 2 | 25 | US | Axitinib, AG-013736 | Columbia University, Pfizer | Pheochromocytoma, Paraganglioma | 12/23 | 01/24 | | |
NCT04010071: Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors |
|
|
| Recruiting | 2 | 60 | RoW | axitinib plus toripalimab | Peking Union Medical College Hospital, Shanghai Junshi Bioscience Co., Ltd. | Hepatobiliary Neoplasm, Liver Neoplasm, Biliary Tract Neoplasms | 01/24 | 06/24 | | |
NCT06211114: Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | PD-(L)1 inhibitor, Axitinib | Peking University Cancer Hospital & Institute | Collecting Duct Carcinoma | 02/26 | 02/27 | | |
SAFH, NCT04387500: Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 41 | RoW | Sintilimab injection plus Inlyta treatment | West China Hospital | Carcinoma, Renal Cell, Fumarate Hydratase Deficiency, Immunotherapy | 03/25 | 01/26 | | |
NCT06279403: Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab, Cytoreductive Nephrectomy, Axitinib | RenJi Hospital | Clear-cell Metastatic Renal Cell Carcinoma, Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy | 03/26 | 03/29 | | |
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling |
|
|
| Recruiting | 2 | 300 | Europe | Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula | Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline | Cancer, Tumors, Neoplasms, Neoplasia | 04/24 | 04/25 | | |
NCT01409200: Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis |
|
|
| Active, not recruiting | 2 | 73 | US | Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Axitinib, AG-013736, AG013736, Inlyta, Radical Prostatectomy, Prostatovesiculectomy, Regional Lymph Node Dissection | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7 | 06/25 | 06/25 | | |
| Recruiting | 2 | 72 | Europe | Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda] | Centre Leon Berard | Papillary Renal Cell Carcinoma Type 2 | 10/24 | 06/26 | | |
NCT03092856: Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer |
|
|
| Active, not recruiting | 2 | 62 | US | Anti-OX40 Antibody PF-04518600, PF-04518600, Axitinib, AG-013736, AG013736, Inlyta, Laboratory Biomarker Analysis, Placebo, placebo therapy, PLCB, sham therapy | University of Southern California, National Cancer Institute (NCI) | Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer | 07/24 | 07/25 | | |
NCT05256472: A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 70 | RoW | AK104, axitinib | Akeso | Renal Cell Carcinoma, First-line Treatment | 07/24 | 12/25 | | |
| Recruiting | 2 | 25 | US | Ipilimumab, Yervoy, Axitinib, Inlyta | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Melanoma | 08/24 | 08/27 | | |
NCT04370509: Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery |
|
|
| Active, not recruiting | 2 | 6 | US | Axitinib (VEGF-TKI), AG-013736, AG013736, Inlyta, Cytoreductive Nephrectomy (CN), Cytoreduction, Nephrectomy, Metastasectomy (MET), Metastasectomy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | University of California, San Francisco, Merck Sharp & Dohme LLC | Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma | 09/24 | 09/25 | | |
NCT05805501: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 210 | Europe, US, RoW | Tobemstomig, RO7247669, Tiragolumab, Pembrolizumab, Keytruda, Axitinib, Inlyta | Hoffmann-La Roche | Renal Cell Carcinoma | 09/24 | 03/26 | | |
NCT02912572: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer |
|
|
| Active, not recruiting | 2 | 106 | US | Avelumab, Talazoparib, Axitinib | Dana-Farber Cancer Institute, Pfizer | Metastatic Endometrial Cancer | 03/25 | 03/27 | | |
ChiCTR2100049523: Recurrent renal cell carcinoma: Radiotherapy, Axitinib and Sintilimab |
|
|
| Not yet recruiting | 2 | 78 | | axitinib ;Sintilimab ;stereotactic body radiotherapy | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Sintilimab and insurance are financed by Innovent Inc., and the rest are self-financing | Renal Cell Carcinoma | | | | |
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 246 | RoW | Axitinib plus Toripalimab, nephrectomy | ZHOU FANGJIAN, Pfizer | Renal Cell Carcinoma, Neoadjuvant | 07/25 | 03/26 | | |
ChiCTR2200067043: Multi-center clinical study of tirelizumab and axitinib combined with stereotactic radiotherapy SBRT in the treatment of oligometastatic advanced renal carcinoma |
|
|
| Not yet recruiting | 2 | 260 | China | tirelizumab+axitinib ;tirelizumab+axitinib+SBRT | The First Affiliated Hospital of Naval Medical University ; The First Affiliated Hospital of Naval Medical University, raise independently | Oligometastatic advanced renal carcinoma | | | | |
| Recruiting | 2 | 720 | Canada | Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib | Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc. | Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors | 01/26 | 01/27 | | |
AxIn, NCT05817903: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients |
|
|
| Recruiting | 2 | 118 | Europe | Axitinib, Inlyta, Nivolumab | Consorzio Oncotech, Pfizer | Metastatic Renal Cell Carcinoma | 04/26 | 04/27 | | |
NCT05384496: Axitinib and Nivolumab for the Treatment of Mucosal Melanoma |
|
|
| Recruiting | 2 | 20 | US | Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib | Memorial Sloan Kettering Cancer Center, Pfizer | Mucosal Melanoma | 05/26 | 05/26 | | |
| Withdrawn | 2 | 25 | NA | Axitinib, Inlyta, Palbociclib, Ibrance, Avelumab, Bavencio | Bradley A. McGregor, MD, Pfizer | Advanced Clear Cell Renal Cell Carcinoma | 08/26 | 08/27 | | |
NEOPAX, NCT05969496: Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus |
|
|
| Recruiting | 2 | 17 | US | Axitinib, Inlyta, Pembrolizumab, Keytruda | University of Colorado, Denver, Cancer League of Colorado | Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis | 11/26 | 11/29 | | |
| Active, not recruiting | 2 | 700 | US | lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib | Strata Oncology, Merck Sharp & Dohme LLC, Pfizer, Gilead Sciences | Cancer, Advanced Solid Tumor | 11/26 | 11/29 | | |
IUNU-RC, NCT05768464: Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, anti-PD-1 monoclonal antibody, Axitinib, TKI | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Non-clear Renal Cell Carcinoma | 12/26 | 12/27 | | |
| Active, not recruiting | 2 | 43 | RoW | Axitinib, Avelumab | Chinese University of Hong Kong | Recurrent or Metastatic NPC | 12/26 | 12/27 | | |
| Recruiting | 2 | 1550 | Europe | Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko | The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life | Cancer, Tumors, Neoplasm, Neoplasia | 09/27 | 12/27 | | |
SAMURAI, NCT05327686: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, Study |
|
|
| Recruiting | 2 | 240 | US | Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Axitinib, AG-013736, AG013736, Inlyta, Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Ablative Radiotherapy, SABER, SABR, SBRT, Stereotactic Ablative Radiation Therapy | NRG Oncology, National Cancer Institute (NCI) | Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma | 06/28 | 06/32 | | |
| Active, not recruiting | 1/2 | 46 | US | Selenomethionine (SLM), Axitinib | Yousef Zakharia, Pfizer | Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) | 08/23 | 05/26 | | |
NCT03172754: Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma |
|
|
| Active, not recruiting | 1/2 | 98 | US | Nivolumab, Axitinib | Fox Chase Cancer Center | Renal Cell Carcinoma | 10/24 | 04/25 | | |
| Active, not recruiting | 1/2 | 34 | Europe, US, RoW | Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT | Pfizer | Carcinoma, Non-Small-Cell Lung | 05/23 | 06/24 | | |
NCT04337970: Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer |
|
|
| Active, not recruiting | 1/2 | 23 | US | Talazoparib, Axitinib | Memorial Sloan Kettering Cancer Center | Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 10/24 | 10/24 | | |
MEPENDAX, NCT06485908: Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma |
|
|
| Not yet recruiting | 1/2 | 40 | NA | administration of axitinib in combination with etoposide | Assistance Publique Hopitaux De Marseille | Medulloblastoma, Ependymoma | 04/26 | 01/30 | | |
NCT05808608: A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma |
|
|
| Not yet recruiting | 1/2 | 33 | RoW | AK104, Axitinib | Hao Zeng | Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | 10/25 | 12/25 | | |
NCT05949632: A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 5 | Europe | INCB099280, axitinib | Incyte Corporation | Advanced Solid Tumors | 12/26 | 12/27 | | |
NCT05363631: Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab |
|
|
| Recruiting | 1/2 | 55 | US | Selenomethionine (SLM), Axitinib, Pembrolizumab | Yousef Zakharia, University of Iowa | Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | 12/26 | 12/26 | | |
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma |
|
|
| Recruiting | 1/2 | 42 | US | Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra | John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb | Unresectable Melanoma | 04/28 | 10/29 | | |
NCT05070221: Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis |
|
|
| Not yet recruiting | 1 | 30 | NA | Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), OH2, Recombinant humanized anti-PD-1 monoclonal antibody for injection, HX-008, Axitinib, Inlyta® | Beijing Cancer Hospital | Melanoma Stage IV | 10/23 | 12/23 | | |
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma |
|
|
| Recruiting | 1 | 88 | RoW | LBL-007, Toripalimab, Axitinib Tablets | Nanjing Leads Biolabs Co.,Ltd | Advanced Melanoma | 08/24 | 12/24 | | |
PIVOT IO 011, NCT04540705: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread |
|
|
| Completed | 1 | 30 | Europe, Canada, US, RoW | Nivolumab, OPDIVO, Axitinib, INLYTA, Cabozantinib, Cabometyx | Bristol-Myers Squibb, Nektar Therapeutics | Renal Cell Carcinoma | 01/24 | 01/24 | | |
NCT04458259: Study of PF-07265807 in Participants With Metastatic Solid Tumors. |
|
|
| Active, not recruiting | 1 | 67 | Europe, Canada, Japan, US, RoW | PF-07265807, ARRY-067, Sasanlimab, PF-06801591; RN-888, Axitinib, AG-013736; Inlyta | Pfizer | Neoplasm Metastasis | 06/24 | 06/24 | | |
| Not yet recruiting | 1 | 60 | RoW | AK104+Axitinib, Cadonilimab, AK112+Axitinib, Ivonescimab | Peking University Cancer Hospital & Institute | Melanoma, Mucosal Melanoma, Metastatic Melanoma | 12/25 | 12/27 | | |
| Terminated | 1 | 5 | US | Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization | Abramson Cancer Center at Penn Medicine, Pfizer | Colorectal Neoplasms Malignant | 04/24 | 04/24 | | |
NCT06161558: Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 70 | US | Erlotinib, Lenvatinib, Axitinib | National Cancer Institute (NCI) | Neoplasms | 01/27 | 11/27 | | |
NCT05904730: Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations |
|
|
| Enrolling by invitation | 1 | 30 | RoW | Axitinib, AG-013736, INLYTA | Lynkcell Europe | Breast Cancer, Ovarian Cancer, Breast Neoplasms, Ovarian Neoplasms, BRCA Mutation, HER2-positive Breast Cancer, HER2-negative Breast Cancer, HER-2 Protein Overexpression | 09/24 | 11/24 | | |
NCT04693468: Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial |
|
|
| Recruiting | 1 | 111 | US | Axitinib, AG-013736, AG013736, Inlyta, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Palbociclib Isethionate, PD 0332991-0054, PF-00080665-73, Talazoparib Tosylate, Talzenna | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | 09/25 | 09/25 | | |
NCT04522323: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 179 | Europe, US, RoW | MEDI5752, Axitinib, Lenvatinib | MedImmune LLC | Advanced Renal Cell Carcinoma | 08/27 | 08/27 | | |
MK-3475A-C18, NCT05017012: A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 72 | Europe, Japan, RoW | MK-3475A, Pembrolizumab, Keytruda, MK-3475, Pemetrexed, Alimta, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Axitinib, Cisplatin, Platinol-AQ | Merck Sharp & Dohme LLC | Advanced or Metastatic Solid Tumors | 09/26 | 09/26 | | |
NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment |
|
|
| No Longer Available | N/A | | Canada, RoW | Axitinib, AG-013736 | Pfizer | Renal Cell Carcinoma | 03/14 | 03/14 | | |
NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial |
|
|
| No Longer Available | N/A | | US | TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda | Tracon Pharmaceuticals Inc. | Solid Tumors | | | | |
ChiCTR2000030405: Study of Efficacy and Safety of Preoperative Axitinib Combined with Toripalimab in Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus: a Clinical Multicentric Prospective Study |
|
|
| Recruiting | N/A | 30 | China | axitinib combined with toripalimab | Chinese PLA General Hospital ; Chinese PLA General Hospital, Project supported by the National Natural Science Foundation of China (Grant No. 81972389) | Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus | | | | |
ChiCTR2000029057: A phase II clinical study of Axitinib combined with Tripletiumab (JS001) and SBRT for locally advanced metastatic renal cell carcinoma |
|
|
| Not yet recruiting | N/A | 26 | | Axitinib, Tripletiumab and SBRT | Sun Yat-sen University Cancer Center; Sun Yat-Sen University Cancer Center, self-raised funding | metastatic renal cell carcinoma | | | | |
NCT05941637: An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF) |
|
|
| Available | N/A | | NA | Axitinib 5 MG, INLYTA, AG-013736 | Lynkcell Europe | Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations | | | | |
NCT05650164: Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) |
|
|
| Completed | N/A | 171 | Japan | avelumab, axitinib | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Renal Cell Carcinoma | 10/23 | 10/23 | | |
| Completed | N/A | 52 | Europe, Japan, US, RoW | axitinib, AG-013736, crizotinib, PF-02341066 | Pfizer | Solid Tumors | 08/23 | 08/23 | | |
